Revisiting STAT3 signalling in cancer: new and unexpected biological functions

The Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins, particularly STAT3, are among the most promising new targets for cancer therapy. In addition to interleukin-6 (IL-6) and its family members, multiple pathways, including G-protein-coupled receptors (GPCRs), Toll-like receptors (TLRs) and microRNAs were recently identified to regulate JAK–STAT signalling in cancer. Well known for its role in tumour cell proliferation, survival, invasion and immunosuppression, JAK–STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche. In addition to its established role as a transcription factor in cancer, STAT3 regulates mitochondrion functions, as well as gene expression through epigenetic mechanisms. Newly identified regulators and functions of JAK–STAT3 in tumours are important targets for potential therapeutic strategies in the treatment of cancer.

[1]  E. Elinav,et al.  Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer , 2013, Proceedings of the National Academy of Sciences.

[2]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[3]  T. Kilpatrick,et al.  LIF receptor signaling modulates neural stem cell renewal , 2004, Molecular and Cellular Neuroscience.

[4]  J. Brugge,et al.  IL-6 involvement in epithelial cancers. , 2007, The Journal of clinical investigation.

[5]  Ke Huang,et al.  STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer. , 2013, Oncology reports.

[6]  S. Spiegel,et al.  Sphingosine Kinases and Sphingosine-1-Phosphate Are Critical for Transforming Growth Factor β-Induced Extracellular Signal-Regulated Kinase 1 and 2 Activation and Promotion of Migration and Invasion of Esophageal Cancer Cells , 2008, Molecular and Cellular Biology.

[7]  Hua Yu,et al.  Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. , 2009, Cancer research.

[8]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[9]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[10]  Y. Horiguchi,et al.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  F. Vesuna,et al.  Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells , 2009, Oncogene.

[12]  S. Ponnusamy,et al.  Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. , 2010, Future oncology.

[13]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[14]  Ying Liang,et al.  Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. , 2013, The Journal of clinical investigation.

[15]  S. Grivennikov.  IL-11: a prominent pro-tumorigenic member of the IL-6 family. , 2013, Cancer cell.

[16]  杉村 啓二郎.  Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma , 2013 .

[17]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[18]  J. Tobias,et al.  Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. , 2008, Cancer research.

[19]  David García-Dorado,et al.  TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. , 2009, Cancer cell.

[20]  J. Lin,et al.  TLR4 knockout protects mice from radiation-induced thymic lymphoma by downregulation of IL6 and miR-21 , 2011, Leukemia.

[21]  J. Radich,et al.  IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. , 2011, Cancer cell.

[22]  Y. Hannun,et al.  Role for sphingosine kinase 1 in colon carcinogenesis , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[24]  M. Golzio,et al.  Sphingosine Kinase-1 Is Central to Androgen-Regulated Prostate Cancer Growth and Survival , 2009, PloS one.

[25]  R. A. Hall,et al.  Fine-tuning of GPCR activity by receptor-interacting proteins , 2009, Nature Reviews Molecular Cell Biology.

[26]  T. Witzig,et al.  Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. , 2012, Blood.

[27]  Yi-Wen Chang,et al.  Direct reprogramming of stem cell properties in colon cancer cells by CD44 , 2011, The EMBO journal.

[28]  John D. Minna,et al.  miR-337-3p and Its Targets STAT3 and RAP1A Modulate Taxane Sensitivity in Non-Small Cell Lung Cancers , 2012, PloS one.

[29]  Valeriy R. Korostyshevskiy,et al.  Mechanisms of Unphosphorylated STAT3 Transcription Factor Binding to DNA* , 2012, The Journal of Biological Chemistry.

[30]  Andrew J. Bannister,et al.  LIF independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease , 2010, Nature Cell Biology.

[31]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[32]  R. Figlin,et al.  Microenvironment and Immunology Targeting Stat3 in the Myeloid Compartment Drastically Improves the in Vivo Antitumor Functions of Adoptively Transferred T Cells , 2022 .

[33]  C. Hunter,et al.  gp130 at the nexus of inflammation, autoimmunity, and cancer , 2010, Journal of leukocyte biology.

[34]  M. Clarke,et al.  Stem Cells and Cancer: Two Faces of Eve , 2006, Cell.

[35]  Michael L. Wang,et al.  Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. , 2010, Blood.

[36]  D. Scadden,et al.  Differential regulation of myeloid leukemias by the bone marrow microenvironment , 2012, Nature Medicine.

[37]  J. Karras,et al.  STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. , 2008, Journal of Clinical Investigation.

[38]  J. P. Hobson,et al.  Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. , 2002, Experimental cell research.

[39]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[40]  M. Kortylewski,et al.  Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. , 2014, Blood.

[41]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[42]  Hsiu‐Po Wang,et al.  Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells , 2007, Oncogene.

[43]  Roberta Galli,et al.  MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response , 2012, Proceedings of the National Academy of Sciences.

[44]  X. Chen,et al.  Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition , 2013, Oncogene.

[45]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[46]  Ursula A White,et al.  The gp130 receptor cytokine family: regulators of adipocyte development and function. , 2011, Current pharmaceutical design.

[47]  Hua Yu,et al.  TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. , 2013, Blood.

[48]  S. Milstien,et al.  The outs and the ins of sphingosine-1-phosphate in immunity , 2011, Nature Reviews Immunology.

[49]  D. Levy,et al.  STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.

[50]  Kevin Struhl,et al.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.

[51]  T. Putoczki,et al.  More than a sidekick: the IL‐6 family cytokine IL‐11 links inflammation to cancer , 2010, Journal of leukocyte biology.

[52]  Hua Yu,et al.  Role of Stat3 in suppressing anti-tumor immunity. , 2008, Current opinion in immunology.

[53]  Ming Li,et al.  The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. , 2013, Neoplasia.

[54]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[55]  A. Thor,et al.  Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers , 2012, Cell cycle.

[56]  Hideaki Tahara,et al.  Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells , 2011, Proceedings of the National Academy of Sciences.

[57]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[58]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  Tongshan Wang,et al.  MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation , 2012, Cancer biology & therapy.

[60]  S. Chiou,et al.  Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway. , 2012, Lung cancer.

[61]  Hua Yu,et al.  G-protein-coupled Receptor Agonist BV8/Prokineticin-2 and STAT3 Protein Form a Feed-forward Loop in Both Normal and Malignant Myeloid Cells* , 2013, The Journal of Biological Chemistry.

[62]  M. Sata,et al.  Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble–IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model , 2009, The Journal of Immunology.

[63]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[64]  Atsuo Ochi,et al.  Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. , 2012, The Journal of clinical investigation.

[65]  R. Proia,et al.  Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone , 2004, Nature Immunology.

[66]  R. Figlin,et al.  S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. , 2012, Cancer cell.

[67]  John K. Heath,et al.  Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides , 1988, Nature.

[68]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[69]  Sarah Spiegel,et al.  Interleukin-1 Regulates the Expression of Sphingosine Kinase 1 in Glioblastoma Cells* , 2009, Journal of Biological Chemistry.

[70]  Libing Song,et al.  Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. , 2013, The Journal of clinical investigation.

[71]  Yiling Lu,et al.  Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. , 2006, Cancer cell.

[72]  Hua Yu,et al.  S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. , 2012, Blood.

[73]  Kevin Struhl,et al.  An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation , 2009, Cell.

[74]  Andrew J. Bannister,et al.  JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin , 2009, Nature.

[75]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[76]  O. Sieber,et al.  Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. , 2013, Cancer cell.

[77]  P. Fawcett,et al.  Function of Mitochondrial Stat3 in Cellular Respiration , 2009, Science.

[78]  S. Milstien,et al.  Sphingosine kinase 1 is required for migration, proliferation and survival of MCF‐7 human breast cancer cells , 2005, FEBS letters.

[79]  S. Lang,et al.  Toll-like Receptors in Regulatory T Cells of Patients With Head and Neck Cancer. , 2010, Archives of otolaryngology--head & neck surgery.

[80]  Shuang Chen,et al.  Toll-Like Receptor 2 Signaling Protects Mice from Tumor Development in a Mouse Model of Colitis-Induced Cancer , 2010, PloS one.

[81]  R. Fischmeister,et al.  A new regulation of IL-6 production in adult cardiomyocytes by beta-adrenergic and IL-1 beta receptors and induction of cellular hypertrophy by IL-6 trans-signalling. , 2010, Cellular signalling.

[82]  Yunlong Liu,et al.  Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance , 2009, Bioinform..

[83]  R. McLendon,et al.  Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth , 2009, Stem cells.

[84]  E. Goetzl,et al.  Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network , 2005, Nature Reviews Immunology.

[85]  Fabio Pellegrini,et al.  Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review , 2013, PloS one.

[86]  D. Banerjee,et al.  Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. , 2010, Experimental cell research.

[87]  Q. Ye,et al.  MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway , 2013, Hepatology.

[88]  Jing-Yuan Fang,et al.  Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway , 2012, Journal of cellular and molecular medicine.

[89]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[90]  S. Pan,et al.  Kaposi's Sarcoma-Associated Herpesvirus (KSHV) vIL-6 Promotes Cell Proliferation and Migration by Upregulating DNMT1 via STAT3 Activation , 2014, PloS one.

[91]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[92]  Y. E. Chin,et al.  Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue , 2005, Science.

[93]  L. Eckmann,et al.  STAT3 and its activators in intestinal defense and mucosal homeostasis , 2010, Current opinion in gastroenterology.

[94]  A. Larner,et al.  Toward a new STATe: the role of STATs in mitochondrial function. , 2014, Seminars in immunology.

[95]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[96]  A. Kowalski-Chauvel,et al.  A Novel Mechanism for JAK2 Activation by a G Protein-coupled Receptor, the CCK2R , 2005, Journal of Biological Chemistry.

[97]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[98]  A. Riggs,et al.  Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation , 2012, Proceedings of the National Academy of Sciences.

[99]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[100]  Y. Saeki,et al.  A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis , 2002, The Journal of experimental medicine.

[101]  Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. , 2012, Cancer research.

[102]  Hua Yu,et al.  Stat3-induced S1PR1 expression is critical for persistent Stat3 activation in tumors , 2010, Nature Medicine.

[103]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[104]  A. Parker,et al.  STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. , 2012, Cancer cell.

[105]  Mallika Singh,et al.  Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression , 2008, Proceedings of the National Academy of Sciences.

[106]  S. Haggarty,et al.  Histone deacetylase 3 as a novel therapeutic target in multiple myeloma , 2014, Leukemia.

[107]  T. Jiang,et al.  TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients , 2010, BMC Cancer.

[108]  David Artis,et al.  Intestinal epithelial cells: regulators of barrier function and immune homeostasis , 2014, Nature Reviews Immunology.

[109]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[110]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[111]  Eric B Haura,et al.  Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.

[112]  A. Riggs,et al.  Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance , 2013, Proceedings of the National Academy of Sciences.

[113]  Eugene Y. Kim,et al.  Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. , 2013, Cancer cell.

[114]  Stem cells: Bad seeds , 2013, Nature.

[115]  R. Figlin,et al.  Myeloid Clusters Are Associated with a Pro-Metastatic Environment and Poor Prognosis in Smoking-Related Early Stage Non-Small Cell Lung Cancer , 2013, PloS one.

[116]  D. Santini,et al.  IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.

[117]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[118]  R. Proia,et al.  The alliance of sphingosine-1-phosphate and its receptors in immunity , 2008, Nature Reviews Immunology.

[119]  Sarah Spiegel,et al.  Sphingosine-1-phosphate signaling and its role in disease. , 2012, Trends in cell biology.

[120]  Timothy C Wang,et al.  Inflammation and cancer: IL-6 and STAT3 complete the link. , 2009, Cancer cell.

[121]  Tetsuro Tsujimoto,et al.  Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis , 2012, PloS one.

[122]  Joel Greshock,et al.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.

[123]  Hua Yu,et al.  Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. , 2014, Cancer research.

[124]  Hua Yu,et al.  Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice , 2009, Glia.

[125]  E. Montserrat,et al.  Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. , 2009, Blood.

[126]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[127]  Jeffrey S. Damrauer,et al.  Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. , 2014, The Journal of clinical investigation.

[128]  Yuan Zhang,et al.  Both miR-17-5p and miR-20a Alleviate Suppressive Potential of Myeloid-Derived Suppressor Cells by Modulating STAT3 Expression , 2011, The Journal of Immunology.

[129]  K. Lim,et al.  Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. , 2007, Genes & development.

[130]  J. Fenton,et al.  Adipokine regulation of colon cancer: Adiponectin attenuates interleukin‐6‐induced colon carcinoma cell proliferation via STAT‐3 , 2010, Molecular carcinogenesis.

[131]  G. Inghirami,et al.  NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. , 2009, Cancer research.

[132]  G. Gallia,et al.  TLR9 is critical for glioma stem cell maintenance and targeting. , 2014, Cancer research.

[133]  K. Struhl,et al.  Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth , 2012, Proceedings of the National Academy of Sciences.

[134]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[135]  Guido Gerken,et al.  Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. , 2011, Gastroenterology.

[136]  Hua Yu,et al.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. , 2008, The Journal of clinical investigation.

[137]  P. Dent,et al.  Mitochondrial Localized Stat3 Promotes Breast Cancer Growth via Phosphorylation of Serine 727* , 2013, The Journal of Biological Chemistry.

[138]  Leah E. Mechanic,et al.  Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. , 2011, Journal of the National Cancer Institute.

[139]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[140]  T. Kwok,et al.  Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 , 2008, Apoptosis.

[141]  Hong-Ying Zhou,et al.  Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin , 2010, Medical oncology.

[142]  Zhaoshi Jiang,et al.  Tumour‐secreted miR‐9 promotes endothelial cell migration and angiogenesis by activating the JAK‐STAT pathway , 2012, The EMBO journal.

[143]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[144]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[145]  R. Medzhitov,et al.  Toll-like receptors and cancer , 2009, Nature Reviews Cancer.

[146]  B. Cochran,et al.  STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells , 2009, Stem cells.

[147]  M. Neurath,et al.  Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. , 2011, The Journal of clinical investigation.

[148]  N. Maitland,et al.  JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. , 2013, Cancer research.

[149]  F. Lee,et al.  The genes for leukemia inhibitory factor and interleukin-6 are expressed in mouse blastocysts prior to the onset of hemopoiesis , 1990, Molecular and cellular biology.

[150]  Hua Yu,et al.  S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3. , 2014, Cell reports.

[151]  D. Levy,et al.  Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation , 2009, Science.

[152]  R. McLendon,et al.  Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. , 2011, Cancer cell.

[153]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[154]  Xin-Yuan Fu,et al.  Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype. , 2012, Blood.